^
    No biomarker
    Prostate Cancer
    enzalutamide
    Sensitive
    :
    A1
    Astellas Press Release - 3d
    No biomarker
    Prostate Cancer
    apalutamide
    Sensitive
    :
    A1
    J Clin Oncol - 1wk
    NEIL3 deletion
    Prostate Cancer
    enzalutamide
    Resistant
    :
    D
    Int J Mol Sci - 3wk
    No biomarker
    Prostate Cancer
    histrelin acetate
    Sensitive
    :
    A1
    No biomarker
    Prostate Cancer
    cabazitaxel
    Sensitive
    :
    A1
    BRCA2 mutation
    Prostate Cancer
    olaparib
    Sensitive
    :
    A1
    BRCA1 mutation
    Prostate Cancer
    olaparib
    Sensitive
    :
    A1
    No biomarker
    Prostate Cancer
    relugolix
    Sensitive
    :
    A1
    No biomarker
    Prostate Cancer
    docetaxel + prednisone
    Sensitive
    :
    A1
    No biomarker
    Prostate Cancer
    abiraterone acetate
    Sensitive
    :
    A1
    No biomarker
    Prostate Cancer
    degarelix
    Sensitive
    :
    A1
    ATM mutation
    Prostate Cancer
    olaparib
    Sensitive
    :
    A1
    No biomarker
    Prostate Cancer
    darolutamide
    Sensitive
    :
    A1
    BRCA1 mutation
    Prostate Cancer
    rucaparib
    Sensitive
    :
    A1
    BRCA2 mutation
    Prostate Cancer
    rucaparib
    Sensitive
    :
    A1
    HRD
    Prostate Cancer
    olaparib
    Sensitive
    :
    A1
    No biomarker
    Prostate Cancer
    zoledronic acid
    Sensitive
    :
    A1
    No biomarker
    Prostate Cancer
    triptorelin
    Sensitive
    :
    A1
    MSI-H/dMMR
    Prostate Cancer
    pembrolizumab
    Sensitive
    :
    A2
    No biomarker
    Prostate Cancer
    mitoxantrone
    Sensitive
    :
    A2
    No biomarker
    Prostate Cancer
    etoposide IV
    Sensitive
    :
    A2
    No biomarker
    Prostate Cancer
    atezolizumab
    Sensitive
    :
    A2
    No biomarker
    Prostate Cancer
    docetaxel
    Sensitive
    :
    A2
    CDK12 mutation
    Prostate Cancer
    olaparib
    Sensitive
    :
    A2
    PALB2 mutation
    Prostate Cancer
    olaparib
    Sensitive
    :
    A2
    CHEK2 mutation
    Prostate Cancer
    olaparib
    Sensitive
    :
    A2
    CHEK1 mutation
    Prostate Cancer
    olaparib
    Sensitive
    :
    A2
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES